Is BPC-157 Legal Now? FDA Peptide Status, October 2026

As of October 9, 2026, BPC-157 is not an FDA-approved drug, and the regulation that lists which bulk ingredients 503A compounding pharmacies may use, 21 CFR 216.23, names six substances and no peptides (eCFR, up to date as of October 7, 2026).

What changed in 2026 is the direction of travel. In April, BPC-157 and several other peptides moved off FDA’s Category 2 “significant safety risks” table after their nominations were withdrawn (FDA). In July, an FDA advisory committee recommended adding six peptides to the 503A list (NPR). FDA still has to act on that advice.

FDA’s Pharmacy Compounding Advisory Committee met on July 23–24, 2026 to consider seven peptides. FDA’s own reviewers proposed that BPC-157 (free base and acetate) not be added to the 503A bulks list (FDA slides).

The committee voted the other way. BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention, and MOTS-c passed 7 to 5 with two abstentions (NBC News). On the second day the panel also backed epitalon and semax and voted against emideltide (DSIP) (NPR).

Sources: vote counts from NBC News and NPR; list status from 21 CFR 216.23.

Advisory committee votes are recommendations. FDA changes the 503A list by rulemaking, and NPR reported that a formal rule could stretch into next year or 2028 (NPR). The current text of 21 CFR 216.23 still lists only Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide (eCFR).

The same regulation says that even listed substances have inadequate data to show safety or efficacy, and that calling a compounded drug made with one “FDA approved” misbrands it (eCFR). So a future listing would allow compounding with a prescription; it would not be an FDA approval.

On October 7, 2026, The Washington Post reported that the administration is paving the way for temporary sale of some unapproved peptides (Washington Post). As of October 9 we found no FDA notice putting such a policy into effect; we will update this page when FDA publishes one.

FDA’s compounding page lists BPC-157 among nominated substances that were withdrawn from Category 2, and keeps its safety summary: compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration,” may have complexities with peptide-related impurities and ingredient characterization, and FDA “lacks sufficient information to know whether the drug would cause harm when administered to humans” (FDA). Evidence: D for human safety (see BPC-157 side effects: the human evidence).

FDA’s briefing document adds that peptides such as BPC-157 can be extremely sensitive to formulation, pH, heat and impurities, which can lead to aggregation and degradation (FDA briefing document). That is the core reason product quality matters as much as the molecule.

TB-500 has a similar entry: FDA says it found no human exposure data for drug products containing the thymosin beta-4 fragment (FDA). For how the two compare in the animal research, see BPC-157 vs TB-500.

Peptides sold online as “for research use only” are not compounded prescriptions and are not FDA-approved. NBC News described them as a legal workaround used by gray-market sellers who claim the products are not meant for humans (NBC News). The July vote did not change their status.

Our deeper explainers: are research peptides legal?, 503A vs 503B compounding pharmacies and how peptide purity is tested.

• A Federal Register proposed rule to add any of the six peptides to 21 CFR 216.23, followed by a comment period and a final rule.
• Any FDA notice changing how it treats these substances while rulemaking is pending.
• Updates to FDA’s Category 2 page, which was last updated April 22, 2026 (FDA).

For background on the earlier changes, see our Category 2 peptide list explainer and the BPC-157 reference page.